Lake Street Private Wealth LLC Sells 9,559 Shares of Enfusion, Inc. (NYSE:ENFN)

Lake Street Private Wealth LLC cut its position in Enfusion, Inc. (NYSE:ENFN) by 38.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 15,441 shares of the company’s stock after selling 9,559 shares during the period. Lake Street Private Wealth LLC’s holdings in Enfusion were worth $159,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Geode Capital Management LLC grew its position in shares of Enfusion by 7.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after buying an additional 70,367 shares during the last quarter. Wellington Management Group LLP grew its holdings in Enfusion by 6.7% in the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock worth $9,265,000 after purchasing an additional 61,032 shares during the last quarter. State Street Corp increased its position in shares of Enfusion by 2.3% during the third quarter. State Street Corp now owns 952,895 shares of the company’s stock worth $9,043,000 after purchasing an additional 21,729 shares in the last quarter. Impax Asset Management Group plc lifted its holdings in shares of Enfusion by 25.4% during the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock valued at $6,424,000 after purchasing an additional 136,948 shares during the last quarter. Finally, Scalar Gauge Management LLC boosted its position in shares of Enfusion by 21.8% in the 2nd quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after purchasing an additional 110,000 shares in the last quarter. 81.05% of the stock is owned by hedge funds and other institutional investors.

Enfusion Stock Up 0.9 %

Shares of NYSE ENFN opened at $11.06 on Friday. Enfusion, Inc. has a 52 week low of $7.52 and a 52 week high of $11.38. The business’s 50 day moving average price is $10.28 and its 200 day moving average price is $9.28. The firm has a market cap of $1.42 billion, a P/E ratio of 276.44, a P/E/G ratio of 1.58 and a beta of 0.95.

Insider Buying and Selling at Enfusion

In other news, CEO Oleg Movchan sold 2,771 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $28,070.23. Following the completion of the transaction, the chief executive officer now owns 526,702 shares of the company’s stock, valued at $5,335,491.26. The trade was a 0.52 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Neal Pawar sold 21,801 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the sale, the chief operating officer now directly owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This trade represents a 1.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,041 shares of company stock worth $597,367. Company insiders own 36.44% of the company’s stock.

Wall Street Analyst Weigh In

ENFN has been the subject of a number of research analyst reports. Piper Sandler increased their price target on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. Stifel Nicolaus increased their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Finally, William Blair reissued a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Enfusion currently has a consensus rating of “Hold” and an average price target of $10.25.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.